WO2006032959A3 - Processes for the preparation of pyrrole derivatives - Google Patents

Processes for the preparation of pyrrole derivatives Download PDF

Info

Publication number
WO2006032959A3
WO2006032959A3 PCT/IB2005/002348 IB2005002348W WO2006032959A3 WO 2006032959 A3 WO2006032959 A3 WO 2006032959A3 IB 2005002348 W IB2005002348 W IB 2005002348W WO 2006032959 A3 WO2006032959 A3 WO 2006032959A3
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
substituted
bonded
pharmaceutically acceptable
group
Prior art date
Application number
PCT/IB2005/002348
Other languages
French (fr)
Other versions
WO2006032959A2 (en
Inventor
Narendra Shriram Joshi
Shekhar Bhaskar Bhirud
Subhash Vishwanath Damle
Original Assignee
Glenmark Pharmaceuticals Ltd
Narendra Shriram Joshi
Shekhar Bhaskar Bhirud
Subhash Vishwanath Damle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd, Narendra Shriram Joshi, Shekhar Bhaskar Bhirud, Subhash Vishwanath Damle filed Critical Glenmark Pharmaceuticals Ltd
Publication of WO2006032959A2 publication Critical patent/WO2006032959A2/en
Publication of WO2006032959A3 publication Critical patent/WO2006032959A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

A process for the preparation of a pyrrole derivative or a racemic mixture, an enantiomer, a diastereoisomer, a mixture thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof comprising reacting an amino compound of the general formula (I), wherein each R is independently hydrogen or a hydrolyzable protecting group, or each R, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R is bonded to the same substituent which is bonded to each oxygen atom to form a hydrolyzable protecting group and R1 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt, with a di-oxo compound of the general formula (II), wherein R2 is 1-naphthyl, 2-naphthyl, a C3-C25 cycloalkyl group, norbornenyl, a substituted or unsubstituted aryl group, benzyl, 2-, 3-, or 4-pyridinyl, or 2-, 3-, 4-pyridinyl-N-oxide, R3 and R4 are independently hydrogen, a lower alkyl, a C3-C25 cycloalkyl group, a substituted or unsubstituted aryl group, cyano, trifluoromethyl, or -CONR6R7 wherein R6 and R7 are independently hydrogen, a lower alkyl or a substituted or unsubstituted aryl group and R5 is a lower alkyl, a C3-C25 cycloalkyl or trifluoromethyl; in the presence of a catalyst and in at least one solvent. Also disclosed is a process for hydrolyzing the pyrrole derivative to provide, for example, atorvastatin or pharmaceutically acceptable salts thereof.
PCT/IB2005/002348 2004-08-06 2005-08-05 Processes for the preparation of pyrrole derivatives WO2006032959A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59938304P 2004-08-06 2004-08-06
US59938204P 2004-08-06 2004-08-06
US60/599,382 2004-08-06
US60/599,383 2004-08-06

Publications (2)

Publication Number Publication Date
WO2006032959A2 WO2006032959A2 (en) 2006-03-30
WO2006032959A3 true WO2006032959A3 (en) 2007-02-22

Family

ID=35871147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002348 WO2006032959A2 (en) 2004-08-06 2005-08-05 Processes for the preparation of pyrrole derivatives

Country Status (1)

Country Link
WO (1) WO2006032959A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566286A (en) * 2005-08-15 2010-06-25 Arrow Int Ltd Crystalline and amorphous sodium atorvastatin
AU2006281237A1 (en) * 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
GB0613567D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
GB0613566D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
KR100850850B1 (en) 2008-01-25 2008-08-06 주식회사종근당 Method for the preparation of atorvastatin and intermediates used therein
CN113105381A (en) * 2021-04-08 2021-07-13 贵州大学 Preparation method of biomass-based 2, 5-dimethyl-N-substituted pyrrole derivative

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
WO2001072706A1 (en) * 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2003024959A1 (en) * 2001-09-14 2003-03-27 EGIS Gyógyszergyár Rt. Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin
WO2005118536A1 (en) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Process for the preparation of atorvastatin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
WO2001072706A1 (en) * 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2003024959A1 (en) * 2001-09-14 2003-03-27 EGIS Gyógyszergyár Rt. Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin
WO2005118536A1 (en) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Process for the preparation of atorvastatin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAUMANN K L ET AL: "THE CONVERGENT SYNTHESIS OF CI-981 AN OPTICALLY ACTIVE HIGHLY POTENT TISSUE SELECTIVE INHIBITOR OF HMG-COA REDUCTASE", 1992, TETRAHEDRON LETTERS, VOL. 33, NR. 17, PAGE(S) 2283-2284, ISSN: 0040-4039, XP002397527 *
WOO PETER W K ET AL: "Atorvastatin, an HMG-CoA reductase inhibitor and efficient lipid-regulating agent. Part I. Synthesis of ring-labeled (14C)atorvastatin", February 1999, JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, VOL. 42, NR. 2, PAGE(S) 121-127, ISSN: 0362-4803, XP002397528 *

Also Published As

Publication number Publication date
WO2006032959A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2006032959A3 (en) Processes for the preparation of pyrrole derivatives
WO2005095409A3 (en) Tetrahydroquinoline derivatives and a process for preparing the same
NO20042584L (en) Dibenzylamine Compounds and Pharmaceutical Use thereof
WO2003028728A8 (en) 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands
WO2004014860A3 (en) Fused heterocyclic compounds as peptidase inhibitors
WO2003045929A1 (en) Bicyclic derivative, process for producing the same, and use
EP1724258A4 (en) Heteroarylphenylurea derivative
WO2007060257A3 (en) Diketopyrrolo-pyrrole compounds
EP1598349A4 (en) Novel 2-pyridinecarboxamide derivatives
WO2003053366A3 (en) Pyrimidine a2b selective antagonist compounds, their synthesis and use
CA2429642A1 (en) Fused heteroaromatic glucokinase activators
EP1496052A4 (en) Novel aminobenzamide derivative
TW200745034A (en) New compounds
WO2008093674A1 (en) Novel thiadiazole derivative having kinase inhibitory activity
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
WO2008114812A1 (en) Jak inhibitor
CA3191532A1 (en) Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
WO2009041559A1 (en) Indazole acrylic acid amide compound
Yuan et al. New efficient synthesis of isoquinoline-1, 3 (2H, 4H)-diones and isoindolin-1-ones via sequential Ugi/cyclization reaction
CA2461060A1 (en) Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
MXPA05003695A (en) New process for the synthesis of 1,3-dihydro-2h-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.
TW200604176A (en) Process for producing bipyridinium compound
WO2004046151A3 (en) Porphyrin derivatives
EP1908752A4 (en) Novel 2-quinolone derivative
DK1340756T3 (en) New beta-lactam compounds and processes for their preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase